04.22.26 -- Drug-Device Combination Products: 4 Evolving Platforms For 2026

For innovative treatments like CAR-T and stem cell transplants, optimal starting material is key. Understanding collection challenges and new solutions helps ensure the best foundation.

Explore how adding a traceless tag enables streamlined affinity purification for recombinant proteins, and how this approach compares with a conventional process in development time, recovery, and purity.

Gain insight into the growing demand for high‑concentration biologics, and the formulation, viscosity, and manufacturing challenges driving new technologies for stable, scalable drug development.

Take an in-depth look at a capture device designed to scale consistently by residence time. The data provided indicates the process can be transferred easily across LC systems to optimize purification.

Discover new affinity chromatography resins for engineered modalities, as well as how they boost yield and reduce aggregation with high-specificity binding and mild elution.

Fill‑finish is evolving as biologics and advanced therapies shift capacity and sterility needs. Automation, emerging tech, and data‑driven methods are boosting efficiency in aseptic production.

Upgrading outdated filling systems is essential for meeting future production demands and regulatory standards. Learn how one manufacturer modernized its approach to ensure compliance and efficiency.